Uploading C:\Program Files\Stnexp\Queries\10543014-rce-narrow.str

```
-----Hy
chain nodes :
1 3 4 5 6 7 9
chain bonds :
1-3 1-4 1-5 1-6 1-7 7-9
exact/norm bonds :
1-3 1-4 1-5 1-6 1-7 7-9
Connectivity:
7:2 E exact RC ring/chain
Match level :
1:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 9:CLASS
Generic attributes :
1:
Saturation
                     : Saturated
Number of Carbon Atoms : 7 or more
Number of Hetero Atoms : Exactly 1
Type of Ring System : Polycyclic
7:
Saturation
                     : Saturated
Element Count :
```

Node 1: Limited C, C7 N,N1

L1 STRUCTURE UPLOADED

```
Uploading C:\Program Files\Stnexp\Oueries\10543014-rce.str
ring nodes :
1 2 3 4 5 6 7 8
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8
```

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom

L1

=> d his

FILE 'REGISTRY' ENTERED AT 19:13:47 ON 09 SEP 2010

STRUCTURE UPLOADED

L2 STRUCTURE UPLOADED L4 36837 S L2 SSS FULL

L4 36837 S L2 SSS FULL L5 82 S L1 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 19:14:53 ON 09 SEP 2010

55 S L5

L6 55 S L5 L7 1 S US200!-543014/APPS

L8 1 S L6 AND L7

L9 54 S L6 NOT L7

FILE 'REGISTRY' ENTERED AT 19:15:14 ON 09 SEP 2010

=> d 11

L1 HAS NO ANSWERS

L1 STR



=> d 12 L2 HAS NO ANSWERS

L2 HAS NO ANSWERS



=> fil caplus

=> d 18 bib abs

VL8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN

IN Watson, Alison Ann; Nash, Robert James; Evinson, Emma Louisa

PA Molecularnature Limited, UK

	PATENT NO.	KIND	DATE	$\sqrt{\text{application no.}}$	DATE
PΙ	WO 2004064715	A2	20040805	WO 2004-GB198	20040121
	WO 2004064715	A.3	20041223		

	ΑU	2004206085	A1	20040805	AU	2004-206085	20040121
	CA	2513881	A1	20040805	CA	2004-2513881	20040121
	EP	1587480	A2	20051026	EP	2004-703841	20040121
	CN	1761666	A	20060419	CN	2004-80007408	20040121
	JP	2006515357	T	20060525	JP	2006-500223	20040121
	NZ	541839	A	20090228	NZ	2004-541839	20040121
	IN	2005DN03195	A	20070413	IN	2005-DN3195	20050719
	US	20070155814	A1	20070705	US	2006-543014	20060815 <
PRAI	GB	2003-1554	A	20030123			
	WO	2004-GB198	A	20040121			

=> d 19 tot bib abs hitstr

ANSWER 1 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PA Summit Corporation PLC, UK APPLICATION NO. PATENT NO. KIND DATE DATE _____ _____ V20091027 WO 2009-GB2554 WO 2010049678 A2 20100506 WO 2010049678 A3 20100826 PRAI GB 2008-19941 A 20081031 GB 2009-6161 GB 2009-8702 A 20090409 A 20090520 GB 2009-14471 A 20090819

 $\sqrt{\text{L9}}$ ANSWER 2 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Chemical Communications (Cambridge, United Kingdom) (2010), 46(15),

√L9 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

PA Summit Corporation Plc., UK; Tinsley, Jonathan Mark; Roach, Alan Geoffrey PATENT NO. KIND DATE APPLICATION NO. DATE _____ _____ V20090910 WO 2010029313 20100318 WO 2009-GB2190 A1 PRAI GB 2008-16600 A 20080911 GB 2008-16602 A 20080911 GB 2008-19528 A 20081024 GB 2008-19533 A 20081024 GB 2009-6206 A 20090409 A 20090409 GB 2009-6209 GB 2009-8677 A 20090520 GB 2009-8697 A 20090520 GB 2009-14473 A 20090819 GB 2009-14474 20090819 A

 $\sqrt{_{
m L9}}$ ANSWER 4 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

PA	Summit Corporation PATENT NO.	PLC, UK KIND	DATE	APPLICATION NO.	DATE
PI	WO 2010015815	A2	20100211	WO 2009-GB1917	V20090804
	WO 2010015815	A3	20100826		
PRAI	GB 2008-14216	A	20080805		
	GB 2008-17437	A	20080924		
	GB 2008-19518	A	20081024		
	GB 2009-6210	A	20090409		
	GB 2009-8672	A	20090520		

.1					
VL9 PA	ANSWER 5 OF 54 Summit Corporation PATENT NO.			APPLICATION NO.	DATE
PI	WO 2010015816	A2	20100211		V20090804
	WO 2010015816	A3	20100826		
PRAI	GB 2008-14322	A	20080806		
	GB 2008-17446	A A	20080924		
	GB 2008-17859	A	20081001		
	GB 2008-19523 GB 2008-19543	A A	20081024 20081024		
	GB 2009-6175	A	20091024		
	GB 2009-6179	A A			
	GB 2009-8661	A	20090409 20090520		
	GB 2009-8666	A	20090520		
√L9 SO	ANSWER 6 OF 54 Journal of Organi				
$\sqrt{_{L9}}$					
so	Journal of Natura	11 Produc	ts (2009),	72(11), 2058-2060	
$\sqrt{_{L9}}$	ANSWER 8 OF 54	CAPLUS	COPYRIGHT 2	2010 ACS on STN	
PA	Biomatrica, Inc.,				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009038853	A2	20090326	WO 2008-US68628	20080627
	WO 2009038853	A3	20091015		00071000
	US 20080176209 EP 2074210	A1 A2	20080724	US 2007-876667 EP 2008-832322	20071022 20080627
			1		20000027
PRAI	US 2007-947275P	P	V20070629	9	
	US 2007-876667	A P	20071022		
	US 2004-560829P US 2005-102588	P 2	20040408 20050408		
	*** *** ****	A2 A2	20051201		
	WO 2006-US45661	A2	20061129		
	WO 2008-US68628	W	20080627		
1					
VL9	ANSWER 9 OF 54	CAPLUS	COPYRIGHT 2	2010 ACS on STN	
so	ChemistryA Euro	pean Jou	rnal (2009)	, 15(7), 1627-1636	
√L9	ANSWER 10 OF 54	CAPLUS	COPYRIGHT	2010 ACS on STN	
PA	Biomatrica, Inc.,	USA			
	PATENT NO.	KIND		APPLICATION NO.	DATE
PΙ	US 20080268514				20080423
	AU 2008275508	A1	20081030 20090115 20090115	AU 2008-275508	20080423
	CA 2684959	A1	20090115	CA 2008-2684959	20080423
	WO 2009009210	A2	20090115	WO 2008-US61332	20080423
	WO 2009009210	A3			
	EP 2118264	A2	20091118	EP 2008-826300 KR 2009-722292	20080423
	KR 2010015889	A	20100212	KK 2009-722292	20080423

	JP	2010524505	T	20100722	JP	2010-506462	20080423
	IN	2009CN06415	A	20100611	IN	2009-CN6415	20091029
	CN	101688170	A	20100331	CN	2008-80021555	20091223
PRAI	US	2007-913781P	P	$\sqrt{20070424}$			
	WO	2008-US61332	W	20080423			

 $\sqrt{\text{L9}}$ ANSWER 11 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Chemistry in Australia (2008), 75(8), 13-14

9 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

- SO e-EROS Encyclopedia of Reagents for Organic Synthesis (2001), No pp. given
- RN 159440-57-0 CAPLUS
- CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

VL9 ANSWER 13 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PA Biomatrica, Inc., USA

PATENT NO.				APPLICATION NO.	DATE
PI	US 20080176209 US 20080176209 US 20050276728 US 20060099567 WO 2007075253 WO 2007075253 WO 2009038853 WO 2009038853 EP 2074210	A1 A1 A1 A2 A3 A2 A3 A2	20080724 20051215 20060511 20070705 20080103 20090326 20091015 20090701	US 2007-876667 US 2005-102588 US 2005-291267 WO 2006-US45661 WO 2008-US68628 EP 2008-832322	20071022 20050408 20051201 20061129 20080627
PRAI	US 20080307117 US 2004-560829P US 2005-102588 US 2005-291267 WO 2006-US45661 US 2007-947275P WO 2005-US12084 US 2007-876667 WO 2008-US68628	A1 P A2 A2 A2 P A2 P A2 W	$\begin{array}{c} 20081211 \\ \sqrt{20040408} \\ 20050408 \\ 20051201 \\ 20061129 \\ 20070629 \\ 20050408 \\ 20071022 \\ 20080627 \end{array}$	US 2008-182926	20080730

VL9 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Organic Letters (2008), 10(13), 2769-2771

 $\sqrt{\text{L9}}$ ANSWER 15 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Tetrahedron (2008), 64(21), 4868-4879

ANSWER 16 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Chemistry--A European Journal (2008), 14(10), 3072-3077 VL9 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PA Institute of Chemistry, Chinese Academy of Sciences, Peop. Rep. China Faming Zhuanli Shenging Gongkai Shuomingshu, 18pp. SO PATENT NO. KIND DATE APPLICATION NO. DATE V20080402 CN 2006-10113357 CN 101153040 A 20060925 CN 100567298 С 20091209 PRAI CN 2006-10113357 20060925 VL9 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Natural Product Communications (2008), 3(1), 41-44 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Natural Product Communications (2008), 3(1), 31-33 √L9 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Natural Product Reports (2008), 25(1), 139-165 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PA Summit Corporation PLC, UK PATENT NO. KIND APPLICATION NO. DATE DATE V20070712 WO 2008009894 A2 20080124 WO 2007-GB2597 WO 2008009894 A3 20080619 PRAT GB 2006-14098 A 20060715 $\sqrt{\text{L9}}$ ANSWER 22 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Journal of Natural Products (2007), 70(6), 993-997 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Science of Synthesis (2006), 20b, 1065-1089 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Tetrahedron: Asymmetry (2006), 17(18), 2702-2712 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PΆ MNL Pharma Limited, UK APPLICATION NO. PATENT NO. KIND DATE DATE V20060120 PI WO 2006077427 A2 20060727 WO 2006-GB209

WO 2006077427 A3 20060914 PRAI GB 2005-1352 A 20050121

VL9 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Journal of Carbohydrate Chemistry (2006), 25(2-3), 281-295

 $\sqrt{_{1.9}}$ ANSWER 27 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN PA MNL Pharma Limited, UK PATENT NO. KIND DATE APPLICATION NO. DATE --------------PI WO 2006067419 A2 20060629 WO 2005-GB4945
WO 2006067419 A3 20070329
PRAI GB 2004-27882 A 20041221 V20051220 VI.9 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN Biomatrica, Inc., USA PATENT NO. KIND DATE APPLICATION NO. DATE ---------PRAI US 2004-560829P P V20040408
US 2005-102588 A2 20050408
WO 2005-US12084 A2 20050408
US 2005-291267 A 20051201
WO 2006-US45661 W 20061129
US 2007-947275P P 20070629

VL9 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Acta Crystallographica, Section E: Structure Reports Online (2006), E62(3), 0928-0930

1

VL9	ANSWER 30 OF 54	CAPLUS	COPYRIGHT	2010 ACS on STN	
PA	MNL Pharma Limited,				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

2005-GB2800 V20050718

PI	WO	2006008493	A1	20060126	WO
PRAI	GB	2004-16419	A	20040723	
	GB	2004-27926	A	20041221	

L9 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

PA	M N L Pharma Limit	ed, UK					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
PI	WO 2005070418	A1	20050804	WO 2005-GB215	20050121		
	AU 2005205962	A1	20050804	AU 2005-205962	20050121		
	AU 2005205962	B2	20100812				
	CA 2553854	A1	20050804	CA 2005-2553854	20050121		
	EP 1711176	A1	20061018	EP 2005-701978	20050121		
	JP 2007518785	T	20070712	JP 2006-550281	20050121		
	US 20090117083	A1	20090507	US 2008-597290	20081230		
PRAI	GB 2004-1238	A	√20040121				
	WO 2005-GB215	W	20050121				

L9 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

P	A MI	N L Pharma Limite	d, UK				
	PA:	TENT NO.	KIND	DATE	APP	LICATION NO.	DATE
P	I WO	2005070415	A1	20050804	WO	2005-GB228	20050121
	AU	2005205968	A1	20050804	AU	2005-205968	20050121
	AU	2005205968	B2	20100729			
	CA	2553986	A1	20050804	CA	2005-2553986	20050121
	EP	1711174	A1	20061018	EP	2005-701990	20050121
	EP	1711174	B1	20080319			
	AT	389397	T	20080415	AT	2005-701990	20050121
	US	20090047306	A1	20090219	US	2008-597296	20081007
P	RAI GB	2004-1239	A	20040121			
	WO	2005-GB228	W	20050121			

VL9 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Tetrahedron (2005), 61(27), 6527-6533


L9 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

FM	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PRAI	JP 2005132837 JP 2003-350926	A A	20050526 20031009	JP 2004-296845	20041008

AB The agents contain metal conjugates of the alkaloids I as $\alpha\text{-glucosidase}$ inhibitors. The agents are manufactured by soaking barks of Syzygium malaccense in MeOH, concentrating the MeOH under a vacuum, partitioning the concentrated residue between EtOAc and H2O, partitioning the aqueous layer between H2O and BuOH, and recovering solid content (called unpurified kavika) from the aqueous layer. Thus, casuarine 6-0- α -glucoside, purified from unpurified kavika, was treated with (AcO)ZIn and the mixture inhibited α -glucosidase at IC50 value 5.7 $\mu\text{g/mL}$. Oral administration of unpurified kavika to streptozotocin-induced or spontaneously diabetic rats suppressed increase in blood sugar after sucrose loading. Unpurified kavika had no acute toxicity.

RN 186795-20-0 CAPLUS

CN α-D-Glucopyranoside, (1S,2S,5R,6R,7R,7aS)-hexahydro-1,6,7-trihydroxy-5-(hydroxymethyl)-1H-pyrrolizin-2-yl (CA INDEX NAME)



√L9 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN


Description: Asymmetry (2004), 15(22), 3635-3642

√AB The reaction of N-benzyloxycarbonyl-L-prolinal (I) with

(methoxycarbonylmethylene)triphenylphosphorane in CH2C12 afforded Me (E)-3- ([2'S)-N-benzyloxycarbonylpyrrolidin-2'-yl]propenoate (II). When the reaction was performed in MeoH, an appreciable amount of the (Z)-isomer was obtained. Both isomers were dihydroxylated to the corresponding 2,3-dihydroxy esters. The stereochem. of the latter compds. could be determined after their transformations into the corresponding 1,2-dihydroxypyrrolizidin-3-ones, e.g. III. Finally, the 1,2-dihydroxypyrrolizidin-3-ones, e.g. III, were reduced to the related pyrrolizidines, e.g. IV.


RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)



RN 240117-30-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-5-methyl-, (1S,2R,3R,5R,6R,7R,7aR)-rel-(+)- (CA INDEX NAME)



VL9 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Acta Crystallographica, Section E: Structure Reports Online (2004),

VAB The title compound [systematic name: (1R,2R,3S,6S,7S,7aR)-3-hydroxymethyl-1,2,6,7-tetrahydroxypyrrolizidine monohydrate or (2S,3R,4R,5R,6S,7S)-2-hydroxymethyl-1-azabicycloj(3.3.0]octan-3,4,6,7-tetrol monohydrate] was formed in a synthetic sequence in which there were several ambiguities in the stereochem. of the reactions. Its crystal structure was determined to resolve these ambiguities. Crystals are tetragonal, space group P41212, with a 7.6230(2), c 33.8174(10) Å; Z = 8, dc = 1.509; R = 0.047, Rw(F2) = 0.072 for 1372 reflections. The structure consists of 3-dimensional H-bonded network.

 $\sqrt{\text{L9}}$ ANSWER 37 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SQ (2003) 459 pp. Avail.: UMI, Order No. DA3091526

 \sqrt{II} 159440-57-0P, (+)-Casuarine

RL: MSC (Miscellaneous); SPN (Synthetic preparation); PREP (Preparation) (asym. induction in heteroatom-substituted aldehydes and total synthesis of (+)-casuarine)

RN 159440-57-0 CAPLUS

√L9 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Tetrahedron Letters (2003), 44(11), 2315-2318

RN 537030-25-4 CAPLUS

CN 3H-Pyrrolizin-3-one, hexahydro-2-hydroxy-6,7-bis(phenylmethoxy)-5-[(phenylmethoxy)methyl]-, (2R,5R,6R,7R,7aR)- (CA INDEX NAME)

VL9 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Tetrahedron: Asymmetry (2003), 14(3), 325-331

CODEN: TASYE3; ISSN: 0957-4166

PB Elsevier Science Ltd.

DT Journal

LA English

 $\sqrt{ ext{AB}}$ The first polyhydroxylated pyrrolizidine alkaloid with a hydroxymethyl group at C-3 was isolated from pods of Alexa leiopetala (Leguminosae) and designated alexine 1. The Australian legume Castanospermum australe is also known to produce the same structural type of pyrrolizidines. There are reports of the isolation of australine (7a-epi-alexine) 2, 1-epi-australine 3, 3-epiaustraline 4, and 7-epi-australine 5 from this plant to date. Their unambiguous syntheses established that the natural product reported as 5 is 2 and the published NMR data for 2 are those of 3. These confusions prompted us to unambiguously confirm the structures and biol, activities of australine isomers and related alkaloids. A careful search for polyhydroxylated pyrrolizidines in seeds of C. australe led to the discovery of three new alkaloids, 2,3-diepi-australine 6, 2,3,7-triepi-australine 7, and the 2-O- β -Dglucopyranoside of 3 (8). Herein, we report the full 13C NMR assignment of alkaloids 1-8 and the glycosidase inhibitory activities of alkaloids 1-8 together with the highly oxygenated pyrrolizidine, casuarine 9, and its 6-0-lpha-D-glucopyranoside 10.

 $\sqrt{\text{L9}}$ ANSWER 40 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN O Synlett (2003), (1), 35-38


NaB Synthesis of (-)-codonopsinine (I) was accomplished in seven steps that involved an addition of five-membered cyclic nitrone II readily obtained from L-xylose, with the Grignard reagent. Nitrone II also underwent intermol. cycloaddn. with several α,β-unsatd. esters to afford cycloadducts, one of which, III, was elaborated to the key intermediate IV for (+)-hyacinthacines Al and A2.

L9 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

- SO Food Style 21 (2001), 5(2), 69-73
- AB A review with refs. on the physiol. effect of nangapiry (Eugenia) which is used in Paraguayan health beverage, covering its blood glucose-inhibitory effect, u-glucosidase-inhibitory effect, and blood pressure-lowering effect, etc. The active components in nangapiry, i.e. uniflorine A, uniflorine B, and (+)-(30,40,58)-l-methivlioridine-3,45-triol are also disclosed.
- RN 159440-57-0 CAPLUS
- CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

- RN 260247-75-4 CAPLUS
- CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6R,7S,7aR)- (CA INDEX NAME)

- L9 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
- AB The water-soluble extract from a Paraguayan natural product, Nangapiry (the leaves of E. uniflora (Myrtaceae)), which has been used as an antidiabetic, showed inhibitory activities on the increase of plasma glucose levels in the sucrose tolerance test (STT) in mice. The fraction adsorbed on a cation exchange resin also inhibited α-glucosidases. From the active fraction, 2 new active compds., uniflorine A (I) and B (II) and the known (+)-(3α,5β)-1-methylpiperidine-3,4,5-triol were isolated. The structures of I and II were determined as (-)-(15,2R,6S,7R,8R,8aR)-1,2,6,7,8-pentahydroxyindolizidine and (+)-(15,2R,5R,7R,8S,8aS)-1,2,5,7,8-pentahydroxyindolizidine by spectral means, resp.
- RN 159440-57-0 CAPLUS
- CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)



RN 260247-75-4 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6R,7S,7aR)- (CA INDEX NAME)

L9 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO (2000) 217 pp. Avail.: UMI, Order No. DA9955629


 \sqrt{IT} 159440-57-0P, (+)-Casuarine

RL: SPN (Synthetic preparation); PREP (Preparation)

(total synthesis of (-)-detoxinine and (+)-casuarine using tandem [4+2]/[3+2] nitroalkene cycloaddns. and cycloaddns. of nitroethylene)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)




VL9 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Analyst (Cambridge, United Kingdom) (2000), 125(8), 1409-1414

NAB Atmospheric pressure chemical ionization (APCI) and electrospray (ES) are compared as ion sources in the anal. of polyhydroxyalkaloids (PHAs) by liquid chromatog, mass spectrometry (LC-MS) and collision induced dissociation (CID) product ion spectra, from tandem mass spectrometry (MS-MS) expts. in a quadrupole ion trap, are reported for 12 naturally occurring PHAs. APCI was found to be a more useful source than ES, as APCI could be used to generate deprotonated mol. ions in neg. mode and for some isomeric PHAs the neg. CID product ion spectra were more diagnostic than the pos. product ion spectra. On-column detection limits were also approx. 32 times lower by pos. APCI than ES. The work provides data that will facilitate screening and characterization of this group of important natural products in plant and fungal exts.

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)



VL9 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Journal of Organic Chemistry (2000), 65(10), 2875-2886

AB The first synthesis of (+)-casuarine (I), a pentahydroxy pyrrolizidine alkaloid of the alexine/australine subclass, is described. The key step is a tandem [4 + 2]/[3 + 2] nitroalkene cycloaddn. involving nitrobenzoate (E-OZNCH:CHOBz), chiral vinyl ether II, and vinyl silane III (IDS = SiMeZCMeZCHMEZ), which establishes five of the six stereocenters present in this potent glycosidase inhibitor. The completion of the synthesis requires only four addnl. steps to deliver the final product in 20% overall yield. The conformation and stereochem of the cycloaddn. were discussed.

VL9 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

Tetrahedron: Asymmetry (2000), 11(1), 1-8

NAB Four new polyhydroxypyrrolizidines, hyacinthacines A1, A2, A3 and B3 (I), were isolated from the bulbs of Muscari armeniacum (Hyacinthaceae) in addition to the known hyacinthacine C1, which was isolated from Hyacinthoides non-scripta (Hyacinthaceae). The structures of hyacinthacines A1, A2, A3 and B3 were identified on the basis of extensive NNR studies as (15, 2R, 7R, 7R) -1, 2-dihydroxy-3-hydroxymethylpyrrolizidine, (1R, 2R, 3R, 7R) -1, 2-dihydroxy-3-hydroxymethylpyrrolizidine, (1R, 2R, 3R, 5R, 7R, 7] -1, 2-dihydroxy-3-hydroxymethyl-5-methylpyrrolizidine and (1S, 2R, 3R, 5R, 7R, 7R) -3-hydroxymethyl-5-methyl-1, 2, 7-trihydroxypyrrolizidine, resp., or the corresponding enantiomers. The inhibitory activities of these new hyacinthacines against a variety of qlycosidases are described.

L9 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

IN Momose, Yasunori

PA

 Japan
 PATENT NO.
 KIND
 DATE
 APPLICATION NO.
 DATE


 JP 2000072770
 A
 20000307
 JP 1998-245307
 19980831

PRAI JP 1998-245307 19980831

(-)-(18,2R,65,7R,8R,8aR)-1,2,6,7,8-pentahydroxyindolizidine (I) and (+)-(15,2R,5R,7R,88,8aS)-1,2,5,7,8-pentahydroxyindolizidine (II) contained in E. unifilora are claimed. Also claimed are α -glucosidase inhibitors containing exts. or powder of E. uniflora, useful for treatment of diabetes, obesity, etc. The exts. may contain ≥ 1 selected from I, II, and (+)-(3a,4a,5\))-1-methylpiperidine-3,4,5-triol (III). Isolation of I, II, and III from a hot water extract of E. uniflora and their maltase-inhibiting and sucrase-inhibiting activities were shown. The hot water extract (spray-dried powder) was orally administered to mice together with sucrose to significantly suppressed the increase in blood glucose. Pharmaceutical prepns. containing the exts. were also formulated.

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethy1)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)



RN 260247-75-4 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6R,7S,7aR)- (CA INDEX NAME)

VL9 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Phytochemical Analysis (1999), 10(5), 259-263

NAB Direct MS anal., utilizing first-order MS and subsequent MS2 and MS3 product ion analyses, is shown to provide a rapid means of characterizing polyhydroxyalkaloid glycosides and aglycons in aqueous methanol plant exts. that have been crudely purified on ion exchange resin. Anal. of species known to synthesize polyhydroxyalkaloids resulted in the discovery of the first diglycosides of these compds. These were detected in Omphalea diandra and Syzygium oleosum. A monoglycoside was also detected as a minor component in Castanospermum australe.

VL9 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Organic Letters (1999), 1(8), 1311-1314

VAB The first synthesis of (+)-casuarine (I), a pentahydroxy pyrrolizidine alkaloid, is described. The key bond-forming events occur in a tandem (4 + 2)/(3 + 2) nitroalkene cycloaddn. involving nitroalkene (E)-O2NCH-CHOCOPh), chiral vinyl ether (II), and vinyl silane (2)-PhMe25iCH-CHCCCH20COPh. This process also creates five of the six stereocenters present in this potent glycosidase inhibitor. Completion of the synthesis required only four addnl. steps and delivered (+)-casuarine in 20% overall vield.

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

L9 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Carbohydrate Research (1999), 316(1-4), 95-103

AB Aqueous ethanol exts. from the immature fruits and stalks of bluebell (Hyacinthoides non-scripta) were subjected to various ion-exchange column chromatog. steps to give 1,4-dideoxy-1,4-imino-D-arabinitol (I), 2(R),5(R)bis(hydroxymethyl)-3(R),4(R)-dihydroxypyrrolidine (DMDP) (II), 6-deoxy-6-C-(2,5-dihydroxyhexyl)-DMDP (III), 2,5-dideoxy-2,5-imino-DL-qlycero-D-mannoheptitol (homoDMDP) (IV), homoDMDP-7-0-apioside (V), homoDMDP-7-0-8-Dxylopyranoside (VI), (1S*, 2R*, 3R*, 5R*, 7aR*)-1, 2-dihydroxy-3, 5dihydroxymethylpyrrolizidine (VII), and (15*,2R*,3R*,5R*,6R*,7R*,7aR*)-3hydroxymethyl-5-methyl-1,2,6,7- tetrahydroxypyrrolizidine (VIII). Bulbs of Scilla campanulata (Hyacinthaceae) yielded (1S*, 2R*, 3R*, 5S*, 7aR*)-1, 2dihydroxy-3,5-dihydroxy- methylpyrrolizidine (IX) in addition to compds. I-VII. Compds. III, VI, VIII, VIII, and IX are new natural products. Compound IV is a potent competitive inhibitor with Ki values of 1.5 uM for Caldocellum saccharolyticum β -glucosidase and 2.2 μ M for bovine liver β -galactosidase. The $7-O-\beta-D-xy$ loside VI was a stronger competitive inhibitor than IV of C. saccharolyticum β -qlucosidase and rat intestinal lactase, with Ki values of 0.06 and 0.07 μM, resp., but a weaker inhibitor of bovine liver βgalactosidase. Furthermore, compound IV is also a competitive inhibitor (Ki = 1.8 µM) of porcine kidney trehalase, but 6 was inactive against this enzyme. 240117-30-0 CAPLUS RN

1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-5-methyl-, (1S,2R,3R,5R,6R,7R,7aR)-rel-(+)- (CA INDEX NAME)

CM

√L9 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN SO Tetrahedron: Asymmetry (1998), 9(14), 2549-2558

VAB The NMR spectra of a number of naturally occurring alexines (tetrahydroxylated pyrrolizidine alkaloids) are analyzed and the consequences of changes in the configuration on the conformation of these bicyclic systems discussed. Unambiguous syntheses of australine (7-epi-alexine) and of 7,7a-epi-alexine have now unequivocally established the structures of two natural products isolated from Castanospermum australe which were insecure due to erroneous NMR data. Chemical shift parameters are unreliable as a method of comparing different samples of identical compds; however, 1H-1H three bond coupling consts. (3JHH) provide easy direct comparison between samples and allow assignments of both the relative configurations for the ring protons and the conformation of the pyrrolizidine framework.

VL9 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Tetrahedron Letters (1997), 38(33), 5869-5872

NAB The key step in the synthesis of four diastereomers of casuarine from eight carbon sugar lactones is the efficient reduction of open chain azidodimesylates by sodium hydrogen telluride (Suzuki-Takaoka reduction) to allow the formation of the pyrrolizidine nucleus by bicyclization. This is the first report of the synthesis of such highly oxygenated pyrrolizidines.

RN 194918-17-7 CAPLUS

CN 1H-Pyrrolizine, hexahydro-1,2,6,7-tetrakis[(triethylsily1)oxy]-3[[(triethylsily1)oxy]methyl]-, (1R,2R,3S,6S,7R,7aR)- (CA INDEX NAME)

RN 194918-07-5 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3S,6S,7R,7aR)- (CA INDEX NAME)

RN 194918-09-7 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7R,7aR)- (CA INDEX NAME)

RN 194918-11-1 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3S,6R,7R,7aR)- (CA INDEX NAME)

RN 194918-12-2 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6R,7R,7aR)- (CA INDEX NAME)

L9 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN

SO Carbohydrate Letters (1996), 2(3), 169-174

AB The isolation, identification and conformational anal. of Casuarine-6- α -D-glucopyranose I from Casuarina equisetifolia L. and Eugenia jambolana Lam. is reported.

IT 159440-57-0P 186795-20-0P

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(isolation of casuarine-6- α -D-glucoside from Casuarina equisetifolia and Eugenia jambolana)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

RN 186795-20-0 CAPLUS

CN α-D-Glucopyranoside, (1S,2S,5R,6R,7R,7aS)-hexahydro-1,6,7-trihydroxy-5-(hydroxymethyl)-1H-pyrrolizin-2-yl (CA INDEX NAME)

- VL9 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2010 ACS on STN
 - Tetrahedron Letters (1994), 35(42), 7849-52
- NAB The isolation from Casuarina equisetifolia bark of casuarine [(1R, 2R, 3R, 6S, 7S, 7aR)-3-(hydroxymethyl)-2, 6, 7-tetrahydroxypyrrolizidine] is reported.
- RN 159440-57-0 CAPLUS
- CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-, (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

=> log hold

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:16:22 ON 09 SEP 2010